Welcome to our dedicated page for Puma Biotechnology news (Ticker: PBYI), a resource for investors and traders seeking the latest updates and insights on Puma Biotechnology stock.
Puma Biotechnology Inc (PBYI) is a biopharmaceutical company focused on advancing targeted therapies for cancer treatment, including its commercialized product NERLYNX® (neratinib) for HER2-positive breast cancer. This page provides investors and healthcare professionals with a comprehensive repository of official company announcements and verified news updates.
Access timely information about clinical trial developments, regulatory milestones, and strategic partnerships directly from the source. Our curated collection includes earnings reports, research advancements, and manufacturing updates related to PBYI's oncology portfolio, including updates on alisertib's development as an aurora kinase A inhibitor.
All content is organized chronologically to help track the company's progress in bringing innovative cancer therapies to market through its risk-mitigated in-licensing strategy. Bookmark this page for convenient access to primary source information about PBYI's contributions to precision medicine in oncology care.
Puma Biotechnology, Inc. (NASDAQ: PBYI) reported its first quarter financial results for 2024, with $40.3 million in product revenue, a net loss of $4.8 million, and $107.2 million in cash reserves. Key milestones include clinical trials for lung and breast cancer treatments. Total revenue was $43.8 million, with operating costs of $46.1 million. Second quarter and full-year 2024 financial outlook projects net product revenue of $43-45 million and $183-190 million, respectively.
FAQ
What is the current stock price of Puma Biotechnology (PBYI)?
What is the market cap of Puma Biotechnology (PBYI)?
